On Thursday, Precision BioSciences Inc.’s (NASDAQ:DTIL) partner iECURE reported clinical efficacy and safety data in the first patient dosed with ECUR-506 in the Phase 1/2 OTC-HOPE study.
ECUR-506 is iECURE’s in vivo gene insertion program designed to treat neonatal-onset Ornithine…